THMO (ThermoGenesis Holdings) Beginning Cash Position: $2.00 Mil (As of Mar. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

THMO ThermoGenesis Holdings Inc THMO
16 GF Score
Price $0.00
View Full Analysis

What is ThermoGenesis Holdings Beginning Cash Position?

ThermoGenesis Holdings THMO 16 Beginning Cash Position is $2.00 Mil as of Mar. 2024. GuruFocus rates THMO with a GF Score™ of 16/100.

ThermoGenesis Holdings's Beginning Cash Position for the quarter that ended in Mar. 2024 was $2.00 Mil.

ThermoGenesis Holdings's quarterly Beginning Cash Position declined from Sep. 2023 ($4.45 Mil) to Dec. 2023 ($4.24 Mil) and declined from Dec. 2023 ($4.24 Mil) to Mar. 2024 ($2.00 Mil).

ThermoGenesis Holdings's annual Beginning Cash Position increased from Dec. 2021 ($7.16 Mil) to Dec. 2022 ($7.28 Mil) but then declined from Dec. 2022 ($7.28 Mil) to Dec. 2023 ($4.18 Mil).

ThermoGenesis Holdings Beginning Cash Position Related Terms

ThermoGenesis Holdings Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for ThermoGenesis Holdings's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ThermoGenesis Holdings Beginning Cash Position Chart

ThermoGenesis Holdings Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.40 4.16 7.16 7.28 4.18

ThermoGenesis Holdings Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.18 5.85 4.45 4.24 2.00
THMO
16GF Score
ThermoGenesis Holdings Inc THMO
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ThermoGenesis Holdings Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of $2.00 Mil mean?
ThermoGenesis Holdings (THMO) has a Beginning Cash Position of $2.00 Mil as of Mar. 2024. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on ThermoGenesis Holdings and its competitors.
Is ThermoGenesis Holdings' Beginning Cash Position too high?
ThermoGenesis Holdings' current Beginning Cash Position is $2.00 Mil. Overall, ThermoGenesis Holdings has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does ThermoGenesis Holdings' Beginning Cash Position compare to MSIU and MOTS?
ThermoGenesis Holdings' Beginning Cash Position of $2.00 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Medical Devices & Instruments company?
A good Beginning Cash Position depends on the Medical Devices & Instruments industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on ThermoGenesis Holdings and its competitors. ThermoGenesis Holdings's current Beginning Cash Position is $2.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ThermoGenesis Holdings stock overvalued right now?
ThermoGenesis Holdings (THMO) has a current Beginning Cash Position of $2.00 Mil. The current Beginning Cash Position is $2.00 Mil. ThermoGenesis Holdings' overall GF Score™ is 16/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For ThermoGenesis Holdings (THMO), the current Beginning Cash Position is $2.00 Mil as of Mar. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

ThermoGenesis Holdings Business Description

Address 2711 Citrus Road, Rancho Cordova, CA, USA, 95742
ThermoGenesis Holdings Inc develops, commercializes and markets a range of automated technologies for CAR-T and other cell-based therapies. The company markets a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally-closed CAR-TXpress platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market. It offers the AutoXpress and BioArchive platforms for automated clinical bio-banking, PXP platform for point-of-care cell-based therapies and CAR-TXpress platform for bio-manufacturing for immuno-oncology applications.
16GF Score

Get the complete analysis for THMO

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price